Patent ID: 9044436
Filing Date: 2015-06-02
Classification: A61K,A61P

Abstract:
1. A method for the treatment of an angiogenesis-related eye disease comprising administering to a human in need thereof between about 0.0001 pg to about 300 pg per eye of a rhodostomin variant comprising an amino acid sequence of SEQ ID NO: 15, or a pharmaceutically acceptable salt of said rhodostomin variant, wherein said angiogenesis-related eye disease is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, retinal angiomatous proliferation, polypoidal choroidal vasculopathy, age-related ischaemia-induced neovascularizing retinopathy, retinopathy of prematurity, and high myopia.